[{"id":"22a22b29-ff5a-48ed-af0f-f0ab690533a4","acronym":"SOLTI NEOPARP","url":"https://clinicaltrials.gov/study/NCT01204125","created_at":"2021-01-18T04:49:29.973Z","updated_at":"2024-07-02T16:37:24.185Z","phase":"Phase 2","brief_title":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT01204125 - SOLTI NEOPARP","lead_sponsor":"Sanofi","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • iniparib (BSI 201)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2017-03-22"}]